Purple Biotech Ltd. (PPBT) has released an update.
Purple Biotech Ltd. has announced exciting developments for its cancer drug NT219, revealing its potential to suppress cancer stem cells and resist tumor recurrence at the upcoming AACR 2024 conference. The drug, which is in a clinical trial phase, has also shown promise in identifying biomarkers for treatment success. Purple Biotech’s continuous progress in oncology drug development marks a significant stride in the fight against solid-tumor cancers.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
